Trial Profile
A phase 2 study of BMS-754807 combined With letrozole or BMS-754807 alone in hormone receptor-positive breast cancer subjects with acquired resistance to non-steroidal aromatase inhibitors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 754807 (Primary) ; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 17 Jun 2019 Status changed from completed to discontinued.
- 07 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.